One of today’s challenges in succeeding in the stock market if you’re a business owner or executive is trying not to get “Amazoned”, or what’s known as having e-commerce giant Amazon run into your competition and target your stocks. This is now becoming a challenge for healthcare providers, pharmaceuticals and drug store chains like Walgreens and CVS who’ve seen Amazon come into their corner. Paul Mampilly is warning investors who hold certain stocks that they could be seeing tremendous losses in the wake of this program. It can be complicated to fully understand how the process of bringing in new drug patents from the pharmaceutical companies to the store shelves works, but there is always a middleman involved that affects the profits.
The business world is in the middle of a massive, transformational change. Investment opportunities are tremendous. Here are a few of my favorites…#IoT #PrecisionMedicine #Investments #StockMarket #Finance #banyanhill #stocks #technologyhttps://t.co/8tx8OtYox5
— Paul Mampilly (@Paul_M_Guru) December 7, 2017
Mampilly explained that the middleman is an important factor in most healthcare companies because they’re responsible for the flow of the new drugs and the profits involved there are also important. But by Amazon coming into this market, these middlemen are no longer going to be reaping profits, and already drug chains like Walgreens have seen their stocks go down in the market. Consumers who use Amazon’s program benefit by not having to go through all the copays and legal details and potentially see relief from bad healthcare policies like the Affordable Care Act. But it’s bad for stockholders because Amazon coming after these stocks means they’re bound to be crushed and not see a rebound unless their business models completely change. So Mampilly warns investors that when they see these stock prices become ultra cheap, they should not buy them.
Paul Mampilly has three newsletters he writes where he discusses which kinds of stocks would be great buys, and which ones you shouldn’t buy. He holds a bachelor’s degree in accounting and finance from Montclair State University and formerly worked for the big banks and and a major hedge fund known as Kinetics International Fund on Wall Street. He earned a solid reputation from fortune 500 clients and investment banks who he managed the funds for, and he also won a competition hosted by the Templeton Foundation in 2008 where he gained 76% on a $50 million investment. But he mysteriously disappeared from Wall Street around 2012 and a few years later revealed that he had done this because he no longer wanted to spend all day in the office, and he wanted his advice to be given to people outside the top 1% circles.
Paul Mampilly had made many personal investments over the years including being an early stock buyer in Facebook and Netflix, and he predicted the rise of Sarepta Therapeutics from startup to a multi-billion dollar pharmaceutical giant. He decided to join Banyan Hill Publishing because this financial resource center values transparency in their information and gives people inside access to stock information that they likely won’t find anywhere else. Mampilly’s first newsletter “Profits Unlimited” picked up over 60,000 subscribers almost overnight, and since then he’s published “Extreme Fortunes” and “True Momentum” for those who’ve become adept at stock investing. He’s received top reviews for his insights with some portfolio holders claiming they’ve made as much as $250,000 in gains.